Dermata prices $3.4 million private placement at $1.46 per share
On August 16, 2026, Dermata Therapeutics agreed to sell 933,064 common shares and pre-funded warrants for 1,360,544 shares in a private placement, with accompanying series E and F warrants. The company expects gross proceeds of about $3.4 million and net proceeds of about $3.2 million, and up to about $6.7 million more if the warrants are exercised in full, though exercise is not assured. The new shares and warrants could dilute existing shareholders, and company insiders, including the CEO and CFO, participated in the offering.
Key points
- Private placement priced at $1.46 per share and accompanying warrants; insiders paid $1.47 per share
- Expected gross proceeds of about $3.4 million, net proceeds of about $3.2 million; closing expected on or about August 18, 2026
- Warrants could add up to about $6.7 million if exercised in full; warrants become exercisable only after stockholder approval
- Company must file a resale registration statement within 60 days of the August 16, 2026 registration rights agreement
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.